Diar500 mg

Diar 500 mg is indicated for the treatment of diarrhea caused by Cryptosporidium parvum, Giardia lamblia and Entamoeba histolytica.

Anti-diarrhoeal Antiprotozoal

Diar 500 mg is a synthetic antiprotozoal agent for oral administration. The antiprotozoal activity of Diar 500 mg is believed to be interference with the Pyruvate Ferredoxin Oxido Reductase (PFOR) enzyme-dependant electron transfer reaction. This reaction is essential for anaerobic energy metabolism of the protozoa. Diar 500 mg and its metabolites, tizoxanid are active in vitro in inhibiting the growth of sporozoites and oocyst of Cryptosporidium parvum and trophozoites of Giardia lamblia.

Age 1-3 years: 1 tea-spoonfull or 5 ml suspension every 12 hours for 3 days. Age 4-11 years: 2 tea-spoonfulls or 10 ml suspension every 12 hours for 3 days.Age 12 years or above: 5 tea-spoonfulls (25 ml) suspension or 1 tablet every 12 hours for 3 days. It is recommended to be administered with food.

Age 1-3 years: 1 tea-spoonfull or 5 ml suspension every 12 hours for 3 days. Age 4-11 years: 2 tea-spoonfulls or 10 ml suspension every 12 hours for 3 days.Age 12 years or above: 5 tea-spoonfulls (25 ml) suspension or 1 tablet every 12 hours for 3 days. It is recommended to be administered with food.

It is highly bound to plasma protein. Therefore, caution should be exercised when administering Diar 500 mg concurrently with other highly plasma protein-bound drugs with narrow therapeutic index.

It is contraindicated in patients with known hypersensitivity to Diar 500 mg or any components of the preparation.

The most frequent side effects, reported by Diar 500 mg are abdominal pain, vomiting and headache. These side effects are typically mild and transient in nature. Very rare side effects include- nausea, anorexia, flatulence, increased appetite, enlarged salivary glands, increased creatinine & SGPT level, pruritus, rhinitis, sweating, dizziness, discolored urine etc.

US FDA pregnancy category of Diar 500 mg is B. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Diar 500 mg have been shown to be excreted in human milk. So, caution should be exercised when Diar 500 mg is administered during lactation.

Diar 500 mg must be administered with caution to patients with hepatic & biliary disease and to patients with renal disease.

Keep in a dry place away from light and heat. Keep out of the reach of children.

Anti-diarrhoeal Antiprotozoal

Diar 500 mg is a synthetic antiprotozoal agent for oral administration. The antiprotozoal activity of Diar 500 mg is believed to be interference with the Pyruvate Ferredoxin Oxido Reductase (PFOR) enzyme-dependant electron transfer reaction. This reaction is essential for anaerobic energy metabolism of the protozoa. Diar 500 mg and its metabolites, tizoxanid are active in vitro in inhibiting the growth of sporozoites and oocyst of Cryptosporidium parvum and trophozoites of Giardia lamblia.

US FDA pregnancy category of Diar 500 mg is B. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Diar 500 mg have been shown to be excreted in human milk. So, caution should be exercised when Diar 500 mg is administered during lactation.